Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TGX-007
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Viralgen
Deal Size : Undisclosed
Deal Type : Collaboration
Viralgen Collaborates with Trogenix to Advance AAV Gene Therapy for Glioblastoma
Details : The collaboration aims to advance the clinical development of Trogenix's rAAV gene therapy, TGX-007, which is being evaluated for glioblastoma.
Product Name : TGX-007
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : TGX-007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Viralgen
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trogenix Unveils Odyssey to Find 'One-nd-Done' Tumor Drugs
Details : Trogenix lead product candidate is being evaluated in preclinical studies for the treatment of patients with aggressive cancers including glioblastoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable